Barbara Bedogni

Barbara Bedogni

Auto-generated profile, based on publicly available information

Barbara Bedogni

Dr. Phillip Frost Department of Dermatology and Cutaneous Surgery, Miller School of Medicine University of Miami Miami Florida USA

Research Focus & Metrics

Academic Career Length

9Years (2018-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
23 September 2020 in Biological Reviews
Verified
Journal Article
Open access
PDF file
JOJames D. B. O'SUllivan
James D. B. O'SUllivan
CNCarina Nicu
Carina Nicu
MPMartin Picard
Martin Picard
JCJeremy Cheret
Jeremy Cheret
BBBarbara Bedogni
Barbara Bedogni
RPRalf Paus
Ralf Paus
Hair greying (canities) is one of the earliest, most visible ageing‐associated phenomena, whose modulation by genetic, psychoemotional, oxidative, senescence‐associated, metabolic and nutritional factors has long attracted skin biologists, dermatologists, and industry. Greying is of profound psychological and commercial relevance in increasingly ageing populations. In addition, the onset and perpetuation of defective melanin production in the human anagen hair follicle pigmentary unit (HFPU) provides a superb model for interrogating the molecular mechanisms of ageing in a complex human mini‐organ, and greying‐associated defects in bulge melanocyte stem cells (MSCs) represent an intriguing system of neural crest‐derived stem cell senescence. Here, we emphasize that human greying invariably begins with the gradual decline in melanogenesis, including reduced tyrosinase activity, defective melanosome transfer and apoptosis of HFPU melanocytes, and is thus a primary event of the anagen hair bulb, not the bulge. Eventually, the bulge MSC pool becomes depleted as well, at which stage greying becomes largely irreversible. There is still no universally accepted model of human hair greying, and the extent of genetic contributions to greying remains unclear. However, oxidative damage likely is a crucial driver of greyingviaits disruption of HFPU melanocyte survival, MSC maintenance, and of the enzymatic apparatus of melanogenesis itself. While neuroendocrine factors [e.g. alpha melanocyte‐stimulating hormone (α‐MSH), adrenocorticotropic hormone (ACTH), ß‐endorphin, corticotropin‐releasing hormone (CRH), thyrotropin‐releasing hormone (TRH)], and micropthalmia‐associated transcription factor (MITF) are well‐known regulators of human hair follicle melanocytes and melanogenesis, how exactly these and other factors [e.g. thyroid hormones, hepatocyte growth factor (HGF), P‐cadherin, peripheral clock activity] modulate greying requires more detailed study. Other important open questions include how HFPU melanocytes age intrinsically, how psychoemotional stress impacts this process, and how current insights into the gerontobiology of the human HFPU can best be translated into retardation or reversal of greying.

20 August 2020 in Clinical Cancer Research
Verified
Journal Article
Open access
PDF file
CMCharles Marusak
Charles Marusak
VTVarsha Thakur
Varsha Thakur
YLYuan Li
Yuan Li
JFJuliano T. Freitas
Juliano T. Freitas
PZPatrick M. Zmina
Patrick M. Zmina
BBBarbara Bedogni
Barbara Bedogni
Purpose: The extracellular matrix (ECM) is an intriguing, yet understudied component of therapy resistance. Here, we investigated the role of ECM remodeling by the collagenase, MT1-MMP, in conferring resistance of v-Raf murine sarcoma viral oncogene homolog B1 (BRAF)-mutant melanoma to BRAF inhibitor (BRAFi) therapy. Experimental Design: Publicly available RNA-sequencing data and reverse phase protein array were used to determine the relevance of MT1-MMP upregulation in BRAFi-resistant melanoma in patients, patient-derived xenografts, and cell line–derived tumors. Short hairpin RNA (shRNA)-mediated knockdown of MT1-MMP, inhibition via the selective MT1-MMP/MMP2 inhibitor, ND322, or overexpression of MT1-MMP was used to assess the role of MT1-MMP in mediating resistance to BRAFi. Results: MT1-MMP was consistently upregulated in posttreatment tumor samples derived from patients upon disease progression and in melanoma xenografts and cell lines that acquired resistance to BRAFi. shRNA- or ND322-mediated inhibition of MT1-MMP synergized with BRAFi leading to resensitization of resistant cells and tumors to BRAFi. The resistant phenotype depends on the ability of cells to cleave the ECM. Resistant cells seeded in MT1-MMP uncleavable matrixes were resensitized to BRAFi similarly to MT1-MMP inhibition. This is due to the inability of cells to activate integrinβ1 (ITGB1)/FAK signaling, as restoration of ITGB1 activity is sufficient to maintain resistance to BRAFi in the context of MT1-MMP inhibition. Finally, the increase in MT1-MMP in BRAFi-resistant cells is TGFβ dependent, as inhibition of TGFβ receptors I/II dampens MT1-MMP overexpression and restores sensitivity to BRAF inhibition. Conclusions: BRAF inhibition results in a selective pressure toward higher expression of MT1-MMP. MT1-MMP is pivotal to an ECM-based signaling pathway that confers resistance to BRAFi therapy.

1 October 2018 in Cancer Letters
Verified
Journal Article
Closed access
HQHong Qiu
Hong Qiu
PZPatrick M. Zmina
Patrick M. Zmina
AHAlex Y. Huang
Alex Y. Huang
DADavid Askew
David Askew
BBBarbara Bedogni
Barbara Bedogni

25 September 2019 in Cancers
Verified
Journal Article
Open access
PDF file
CRCiro Francesco Ruggiero
Ciro Francesco Ruggiero
DMDebora Malpicci
Debora Malpicci
LFLuigi Fattore
Luigi Fattore
GMGabriele Madonna
Gabriele Madonna
VVVito Vanella
Vito Vanella
Gennaro CilibertoGennaro Ciliberto
Gennaro Ciliberto
In recent years the introduction of target therapies with BRAF and MEK inhibitors (MAPKi) and of immunotherapy with anti-CTLA-4 and anti-PD-1 monoclonal antibodies have dramatically improved survival of metastatic melanoma patients. Despite these changes drug resistance remains a major hurdle. Several mechanisms are at the basis of drug resistance. Particular attention has been devoted over the last years to unravel mechanisms at the basis of adaptive/non genetic resistance occurring in BRAF mutated melanomas upon treatment with to MAPKi. In this paper we focus on the involvement of activation of ErbB3 receptor following early exposure of melanoma cells to BRAF or MEK inhibitors, and the following induction of PI3K/AKT pathway. Although different mechanisms have been invoked in the past at the basis of this activation we show here with a combination of approaches that autocrine production of neuregulin by melanoma cells is a major factor responsible for ErbB3 phosphorylation and downstream AKT activation. Interestingly the kinetic of neuregulin production and of the ensuing ErbB3 phosphorylation is different in different melanoma cell lines which underscores the high degree of tumor heterogeneity. Moreover, heterogeneity is further highlighted by the evidence that in different cell lines neuregulin upregulation can occur at the transcriptional or at the post-transcritpional level. Finally we complement our study by showing with a liquid biopsy assay that circulating tumor cells (CTCs) from melanoma patients undergo upregulation of ErbB3 phosphorylation in vivo shortly after initiation of therapy.

1 February 2019 in Cancer Letters
Verified
Journal Article
Closed access
VTVarsha Thakur
Varsha Thakur
KZKeman Zhang
Keman Zhang
ASAlyssa Savadelis
Alyssa Savadelis
PZPatrick Zmina
Patrick Zmina
BABrittany Aguila
Brittany Aguila
BBBarbara Bedogni
Barbara Bedogni

27 May 2025 in Neuro-Oncology
Verified
Journal Article
Closed access
ARAyush B Rana
Ayush B Rana
THTimothy M Horton
Timothy M Horton
VTVijay S Thakur
Vijay S Thakur
DWDazhi Wang
Dazhi Wang
VTVarsha Thakur
Varsha Thakur
SWScott M Welford
Scott M Welford
Background: Metabolic reprogramming in glioblastoma (GBM) is a putative determinant of GBM subtype, malignant cell state, and tumor-immune crosstalk. In the present study, we investigated how polyamine metabolic rewiring contributes to the malignant cell-intrinsic and microenvironment-dependent biological processes underpinning GBM subtype classification. Methods: Liquid chromatography/tandem mass spectrometry was used for polyamine quantification in human and murine GBM tumors and cell lines. Through single-cell RNA sequencing, metabolic profiling, and additional functional experiments, we dissect the malignant cell-intrinsic and paracrine signaling processes regulated by SAT1 (spermidine/spermine-N1-acetyltransferase1) and its product, N1-acetylspermidine. Results: We find that polyamine acetylation is elevated in human and murine GBM tumors and contributes to the classification of mesenchymal/plurimetabolic GBM through both regulation of tumor-cell intrinsic glucose metabolism and by facilitating metabolic crosstalk with tumor-associated macrophages/myeloid cells (TAMs). The impact of SAT1 on tumor cell metabolism is mediated, at least in part, by N1-acetylspermdine, the sole polyamine elevated in human and murine tumors. Furthermore, the relatively high levels of N1-acetylspermidine released by GBM are taken up by myeloid cells to promote intracellular polyamine flux, cellular respiration, and migration. In vivo, both genetic disruption of polyamine acetylation and pharmacological inhibition of polyamine transport reduced myeloid cell infiltration and sensitized tumors to chemoradiation. Conclusions: Collectively, the findings highlight a previously unidentified role for SAT1 and its product, N1-acetylspermidine, in bridging the metabolic activity of tumor cells and TAMs, together promoting mesenchymal/plurimetabolic states and therapeutic resistance in GBM.